Business Description
PHAXIAM Therapeutics SA
ISIN : FR001400K4B1
Compare
Compare
Traded in other countries / regions
2E40.GermanyPHXM.FrancePXMTF.USA0QSS.UK IPO Date
2014-04-15Description
PHAXIAM Therapeutics SA is a biopharmaceutical company developing treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an approach based on the use of phages, natural bacteria-killing viruses. It is developing a portfolio of phages targeting 3 of the resistant and dangerous bacteria, which account for resistant nosocomial infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
6-1 Month Momentum % | -94.57 | |||||
12-1 Month Momentum % | -93.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PHAXIAM Therapeutics SA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0.903 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -1.28 | ||
| 3-Year Sortino Ratio | -1.29 | ||
| Volatility % | 93.16 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | - | ||
| 12-1 Month Momentum % | -93.98 | ||
| 52-Week Range (€) | 0.0282 - 2.1 | ||
| Shares Outstanding (Mil) | 10.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PHAXIAM Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PHAXIAM Therapeutics SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2023-09-18 | 3.58 (-1.39%) |
Show
Entries
PHAXIAM Therapeutics SA Frequently Asked Questions
What is PHAXIAM Therapeutics SA(LTS:0QSS)'s stock price today?
The current price of LTS:0QSS is €0.10. The 52 week high of LTS:0QSS is €2.10 and 52 week low is €0.03.
When is next earnings date of PHAXIAM Therapeutics SA(LTS:0QSS)?
The next earnings date of PHAXIAM Therapeutics SA(LTS:0QSS) is .
Does PHAXIAM Therapeutics SA(LTS:0QSS) pay dividends? If so, how much?
PHAXIAM Therapeutics SA(LTS:0QSS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers